Table 4 Relationship between nuclear ADA3 and nuclear c-MYC co-expression groups with molecular biomarker status within ER+ tumors only (n = 432 cases)
From: ADA3 regulates normal and tumor mammary epithelial cell proliferation through c-MYC
Parameters | ADA3 Nuclear C MYC Nuclear expression phenotypes | ||||||
|---|---|---|---|---|---|---|---|
ADA3low C MYClow N (%) | ADA3high C MYClow N (%) | ADA3low C MYChigh N (%) | ADA3high C MYChigh N (%) | X 2 | P | ||
Patient age | ≤50 | 35 (26.3) | 18 (13.5) | 39 (29.3) | 41(30.8) | 0.469 | 0.936 |
>50 | 78 (26.0) | 38 (12.7) | 82 (27.3) | 102 (34.0) | |||
Menopausal Status | Pre | 35 (24.5) | 19(13.3) | 44 (30.8) | 45 (31.5) | 1.002 | 0.8011 |
Post | 78 (26.9) | 37 (12.8) | 77 (26.6) | 98 (33.8) | |||
Tumor size | ≤2 cm | 65 (24.3) | 34 (12.7) | 74 (27.6) | 95 (35.4) | 1.968 | 0.579 |
>2Â cm | 48(29.3) | 22 (13.4) | 45 (27.4) | 49 (29.9) | |||
Tumor grade | 1 | 18 (22.0) | 14 (17.1) | 17 (20.7) | 33 (40.2) | 15.477 | 0.017 |
2 | 44 (25.6) | 16 (9.3) | 44 (25.6) | 68 (39.5) | |||
3 | 51 (28.5) | 26 (14.5) | 59 (33.0) | 43 (24.0) | |||
Tubules | 1 | 5 (22.7) | 7 (31.8) | 5 (22.7) | 5 (22.7) | 9.813 | 0.133 |
2 | 41 (25.2) | 17 (10.4) | 51 (31.3) | 54 (33.1) | |||
3 | 65 (28.1) | 27 (11.7) | 60 (26.0) | 79 (34.2) | |||
Pleomorphism | 1 | 1 (14.3) | 1 (14.3) | 3 (42.9) | 2 (28.6) | 19.460 | 0.003 |
2 | 52 (24.9) | 31 (14.8) | 42 (20.1) | 84 (40.2) | |||
3 | 58 (29.1) | 19 (9.5) | 71 (35.7) | 51 (25.6) | |||
Mitosis | 1 | 40 (24.0) | 22 (13.2) | 38 (22.8) | 67 (40.1) | 10.175 | 0.117 |
2 | 23 (25.3) | 8 (8.8) | 30 (33.0) | 30 (33.0) | |||
3 | 48 (30.4) | 21 (13.3) | 48 (30.4) | 41 (25.9) | |||
Axillary nodal stage | 1 | 58 (24.6) | 35 (14.8) | 61 (25.8) | 82 (34.7) | 3.652 | 0.724 |
2 | 43 (26.7 | 17 (10.6) | 50 (31.1) | 51 (31.7) | |||
3 | 12 (32.4) | 4 (10.8) | 10 (27.0) | 11 (29.7) | |||
NPI | Good | 27 (18.6) | 20 (13.8) | 37 (25.5) | 61 (42.1) | 15.643 | 0.016 |
Moderate | 63 (29.3) | 31(14.4) | 56(26.0) | 65(30.2) | |||
Poor | 23 (31.5) | 5(6.8) | 27 (37.0) | 18 (24.7) | |||
Lymphovascular Invasion (LVI) | Negative | 75 (26.2) | 44 (15.4) | 67(23.4) | 100 (35.0) | 11.090 | 0.011 |
Positive | 37 (25.3) | 12 (8.2) | 54 (37.0) | 43 (29.5) | |||
Tumor type | Invasive Ductal/NST | 71 (31.0) | 28 (12.2) | 71 (31.0) | 59 (25.8) | 44.333 | <0.001 |
Invasive Lobular | 13 (22.4) | 8 (13.8) | 4 (6.9) | 33 (56.9) | |||
Medullary-like | 0(0) | 1(33.3) | 2 (66.7) | 0 (0) | |||
Excellent Prognostic Special types* | 5 (26.3) | 6 (31.6) | 5 (26.3) | 3 (15.8) | |||
Tubular Mixed | 16 (17.4) | 11 (12.0) | 28 (30.4) | 37 (40.2) | |||
Mixed NST & Lobular | 4 (19.0) | 2 (9.5) | 6 (28.6) | 9 (42.9) | |||
Mixed NST &other special types | 2 (28.6) | 0 | 3 (42.9) | 2 (28.6) | |||
Ki67 labelling Index | Low | 35 (23.0) | 25 (14.8) | 33 (21.9) | 68 (40.4) | 11.217 | 0.011 |
High | 49 (29.9) | 22 (10.8) | 38 (36.3) | 50 (23.0) | |||
p27 | Low | 61 (35.5) | 21 (12.2) | 47 (27.3) | 43 (25.0) | 18.993 | <0.001 |
High | 37 (16.9) | 32 (14.6) | 67 (30.6) | 83 (37.9) | |||